Development of venous thromboembolism in patients with hereditary thrombophilic risk factors and evaluation of genetic and biochemical parameters affecting development of venous thromboembolism

dc.authorid0000-0002-6107-2943
dc.authorid0000-0002-8212-7149
dc.authorid0000-0003-0021-6509
dc.authorid0000-0003-4709-4705
dc.authorid0000-0003-3655-1595
dc.authorid0000-0002-5711-0038
dc.authorid0000-0002-5330-920X
dc.contributor.authorKorkmaz, Ufuk Turan Kürşat
dc.contributor.authorÇetinkaya, Ayhan
dc.contributor.authorYüksel, Ahmet
dc.contributor.authorVelioğlu, Yusuf
dc.contributor.authorUçaroğlu, Erhan Renan
dc.contributor.authorArslan, Ali Osman
dc.contributor.authorErdem, Kemalettin
dc.date.accessioned2021-06-23T18:27:11Z
dc.date.available2021-06-23T18:27:11Z
dc.date.issued2020
dc.departmentBAİBÜ, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.departmentBAİBÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü
dc.description.abstractObjectives: To evaluate patients diagnosed with venous thromboembolism (VTE) in terms of hereditary thrombophilic risk factors and to assess genetic and biochemical factors affecting the development of VTE. Methods: Sixty patients with VTE and 23 control subjects without VTE were retrospectively evaluated. Prevalence of thrombophilic risk factors and parameters like demographic data, clinical follow-up duration were examined with genetic, biochemical and radiological investigations. Results: Mutations were detected in the genes of Factor V Leiden in 37.4%, Factor II in 13.4%, Methylenetetrahydrofolate reductase C677 in 47.5%, Methylenetetrahydrofolate reductase A1298C in 53.3%, Plasminogen activator inhibitor-1 in 31.6%, Angiotensin converting enzyme in 39.0%, and Factor V H1299R in 8.3% of patients. Protein C deficiency was detected in 25 patients (41.7%), free Protein S deficiency was detected in 25 patients (41.7%) in study group and 3 subjects (13.0%) in control group, and this difference was statistically significant (p=0.023). Antithrombin III deficiency was detected in 1 patient (1.7%) in study group. Elevated homocysteine was higher in study group compared to controls, and the difference was statistically significant (p=0.02). Conclusion: Determination of hereditary risk factors in VTE patients will provide family members who have hereditary risk factors, but did not suffer attack to be protected against thromboembolic attacks by taking simple measures against acquired factors.en_US
dc.identifier.doi10.14744/ejmi.2019.62618
dc.identifier.endpage311en_US
dc.identifier.issn2602-3164
dc.identifier.issn2602-3164
dc.identifier.issue3en_US
dc.identifier.startpage304en_US
dc.identifier.trdizinid372300en_US
dc.identifier.urihttps://doi.org/10.14744/ejmi.2019.62618
dc.identifier.urihttps://app.trdizin.gov.tr/makale/TXpjeU16QXdNQT09
dc.identifier.urihttps://hdl.handle.net/20.500.12491/1616
dc.identifier.volume4en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.institutionauthorKorkmaz, Ufuk Turan Kürşat
dc.institutionauthorÇetinkaya, Ayhan
dc.institutionauthorYüksel, Ahmet
dc.institutionauthorVelioğlu, Yusuf
dc.institutionauthorUçaroğlu, Erhan Renan
dc.institutionauthorArslan, Ali Osman
dc.institutionauthorErdem, Kemalettin
dc.language.isoenen_US
dc.relation.ispartofEurasian Journal of Medical Investigationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHereditary Thrombophilia
dc.subjectSuperficial Thrombophlebitis
dc.subjectVenous Thromboembolism
dc.titleDevelopment of venous thromboembolism in patients with hereditary thrombophilic risk factors and evaluation of genetic and biochemical parameters affecting development of venous thromboembolismen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
ufuk-turan-kursat-korkmaz.pdf
Boyut:
578.1 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/ Full text